Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss

Costco, Sanofi and SAP reportedly raised dividends by more than 10%, signaling increased shareholder capital returns. Sanofi is also prioritizing Specialty Care growth while preparing for Dupixent’s expected loss of exclusivity in the early 2030s, creating a longer-term revenue replacement challenge.